Validation of Quantitative Measurements of LVEF by Different Software Programs for Gated Myocardial Perfusion SPECT
Authors | Year | Software | Gold standard | No. of patients | r | Isotope | Reference |
---|---|---|---|---|---|---|---|
Ioannidis et al. | 2002 | QGS | MRI | 0.89 | 62 | ||
Baba et al. | 2002 | QGS | Contrast ventriculography | 20 | 0.80 | 201Tl | 63 |
Itti et al. | 2001 | QGS | ERNA | 50 | 0.88–0.92 | 201Tl | 64 |
Vourvouri et al. | 2001 | QGS | 2D Echo | 32 | 0.83 | 65 | |
Higuchi et al. | 2001 | QGS | ERNA | 0.90 | 66 | ||
Germano et al. | 1995 | QGS | FPRNA | 65 | 0.90 | 99mTc-Sestamibi | 10 |
Faber et al. | 1999 | ECTb | MRI | 10 | 0.88 | 99mTc-Sestamibi | 67 |
FPRNA | 79 | 0.82 | |||||
Vallejo et al. | 2000 | QGS | MRI | 16 (canine) | 0.51 | 99mTc-Sestamibi | 13 |
Tadamura et al. | 1999 | QGS | MRI | 20 | 0.92 | 201Tl | 68 |
0.94 | 99mTc-Sestamibi | ||||||
Yoshioka et al. | 1999 | QGS | FPRNA | 21 | 0.91 | 99mTc-Tetrofosmin | 69 |
0.87 | |||||||
Vallejo et al. | 2000 | QGS | FPRNA | 400 | 0.66 | 14 | |
Nichols et al. | 1998 | LV angiography | 58 | 0.86 | 99mTc-Sestamibi | 70 | |
Nichols et al. | 1997 | FPRNA | 22 | 0.90 | 99mTc-Sestamibi | 71 | |
Atsma et al. | 2000 | QGS | Contrast ventriculography | 74 | 0.84 | 99mTc-Tetrofosmin | 72 |
Wright et al. | 2000 | QGS | ERNA | 70 | 0.70–0.71 | 201Tl (low dose) | 73 |
Bax et al. | 2000 | QGS | MRI | 22 | 0.90 | 99mTc-Tetrofosmin | 74 |
Bavelaar-Croon et al. | 2000 | QGS | MRI | 21 | 0.85 | 75 | |
Cwajg et al. | 2000 | 2D Echo | 109 | ≥0.68 | 201Tl | 76 | |
99mTc | |||||||
Nichols et al. | 2000 | SPECT | 2D Echo | 33 | 0.92 overall | 77 | |
EF | 0.82 SPECT EF | ||||||
QGS | 0.75 QGS | ||||||
ECTb | 0.72 ECTb | ||||||
He et al. | 1999 | FPRNA | 63 | 0.84–0.85 | 99mTc-Sestamibi | 78 | |
201Tl | |||||||
Vaduganathan et al. | 1999 | MRI | 25 | 0.93 | 99mTc | 79 | |
Inubushi et al. | 1999 | QGS | FPRNA | 44 | 0.919 | 99mTc-Sestamibi | 80 |
Nichols et al. | 1996 | ERNA | 75 | 0.87 | 99mTc-Sestamibi | 81 | |
FPRNA | 65 | 0.87 | |||||
Nakajima et al. | 2001 | QGS | ERNA | 30 | 0.82 QGS | 18 | |
ECTb | 0.78 ECTb | ||||||
4D-MSPECT | 0.69 4D-MSPECT | ||||||
pFAST* | 0.84 pFAST* | ||||||
Everaert et al. | 1997 | QGS | ERNA | 40 | 0.89 QGS | 99mTc-Tetrofosmin | 82 |
Stanford | 0.93 SU | ||||||
Chua et al. | 2000 | QGS | ERNA | 62 | 0.94 | 99mTc | 83 |
Abe et al. | 2000 | QGS | Contrast ventriculography | 229 | 0.78 | 99mTc-Tetrofosmin | 84 |
Manrique et al. | 2000 | QGS | ERNA | 55 | 0.71–0.94 | 201Tl | 85 |
Williams and Taillon | 1996 | University of Chicago image inversion | FPRNA | 38 | 0.83 | 99mTc-Sestamibi | 86 |
Contrast ventriculography | 54 | 0.93 |
↵* Perfusion and function analysis for gated SPECT.
ERNA = equilibrium radionuclide angiography; 2D Echo = 2-dimensional echocardiography; FPRNA = first-pass radionuclide angiography.